FDA Investigator Barbara I Rogolsky
Barbara I Rogolsky has inspections in 3 countries as of 11 Nov 2022. Barbara I Rogolsky has collaborated with a combinined 688 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
3
Last Inspection Date:
11 Nov 2022
Investigator Role:
FDA Investigation Participant
Redica ID:
Country:
Japan,
United States of America,
India
Co-Investigator(s):
Angela E Glenn,
Barbara J Ragolsky,
Barbara L Rogolsky,
Brett R Havranek,
Bryce A Hammer,
Cheryl A Clausen,
Dana D Carter, SR DDS,
Devaugh Edwards,
Devaughn Edwards,
Helen Verdel,
Janete A Eaker,
Jogy George,
Johnson,
Joseph R Lambert,
Julianne C Mccullough,
Kellia N Hicks,
Kenneth H Williams,
Kenneth Nieves,
Lori A Gioia,
Luis A Dasta,
Martin J Kurek,
Matthew M Henciak,
Megan A Haggerty,
Melissa J Garcia,
Michael A Charles,
Michael A Feingold,
Nicole J Conklin,
Paige E Shelborne,
Paige E Wilson,
Robert J Martin,
Rozelle G Smith,
Saleem A Akhtar,
State Agency,
Stroman,
Tamara J Genetti,
Tamara J Umscheid,
Vani Mathur Richards,
Victoria A Wagoner,
Vlada Matusovsky,
Yumi J Hiramine
Barbara I Rogolsky's Documents
Publish Date | Document Type | Title |
---|---|---|
November, 2002 | FDA 483 | CIPLA LIMITED - Form 483, 2002-11-14 |
April, 2002 | EIR | Kyorin Pharmaceutical Group Facilities Co., Ltd. - EIR, 2002-04-11 |
November, 2002 | EIR | CIPLA LIMITED - EIR, 2003-01-17 |
April, 2004 | FDA 483 | Wilbur-Ellis Nutrition, LLC - Form 483, 2004-04-29 |
April, 2002 | FDA 483 | Kyorin Pharmaceutical Group Facilities Co., Ltd. - Form 483, 2002-04-11 |
April, 2004 | EIR | Wilbur-Ellis Nutrition, LLC - EIR, 2004-04-29 |
November, 2002 | FDA 483 Response | CIPLA LIMITED - Form 483R, 2002-12-02 |
Experience Redica System's NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more